Taking place at the prestigious Caixa Forum venue in central Madrid, it featured some of the most important international experts in the medical cannabis field coming from Israel, the United States, Chile and Spain. Topping the list was research scientist, Professor Raphael Mechoulam, whose discovery of the cannabinoid THC in 1964, paved the way for all consequent research and developments in medical cannabis.
Also present were eminent Spanish scientists such as Manuel Guzmán, Professor of Biochemistry and Molecular Biology at Madrid Complutense, a trailblazer in cannabinoid research into neurodegenerative diseases, Cristina Sanchez, a fellow Spanish scientist at the forefront of the antitumoral use of cannabinoids in oncology and Mara Gordon, a specialist in designing medical cannabis treatment protocols for the seriously ill in California.
The sell out event was designed as a forum for anyone wanting to inform themselves about the medicinal potential of cannabis and attendees included conventional medical professionals, politicians from Spanish political parties and patients who currently treat their health conditions with cannabis.
Endoca were thrilled to lend their support to this event as official sponsors, sharing the common goals expressed during the day, such as campaigning for a change in the status of medicinal cannabis, a need for more clinical trials and a greater regulation of cannabis products, ensuring safety, quality and consistency for patients.
A selection of our products
BOARD OF DIRECTORS
Carolina Pérez, President
Javier Pedraza, Vice-president
Cristina Sánchez, Secretary
Guillermo Velasco, Treasurer
Ekaitz Agirregoitia, Member
José Carlos Bouso, Member
Mariano García de Palau, Member
Manuel Guzmán, Member
José Martínez-Orgado, Member
Joan Parés, Member
Professor of Medicinal Chemistry at Hebrew University (Jerusalem, Israel), he is a world-wide recognized leader on cannabis research and the responsible, among many other achievements, of the isolation and characterization of the main marihuana-derived and endogenously produced cannabinoids (THC and anandamide, respectively).
ANA MARÍA GAZMURI
Chief Executive Officer of Daya Foundation, a Chilean non-profit organization aimed at researching and promoting alter-native therapies to alleviate human suffer-ing. Since 2012 she is involved in Drug Policies in general and medicinal cannabis in particular. In early 2014 she created Daya Foundation to work in this field from an institutional position.
Process Engineer specialized in the development of cannabis extract treatment protocols for seriously ill patients in California. She is the co-founder of Aunt Zelda’s and Zelda Therapeutics. More recently, she created CDRMed, a software that will enable physicians and medical health professionals to make treatment recommendations based on the latest and highest-quality data.
Professor of Biochemistry and Molecular Biology at Complutense University (Madrid). His research is focused on under-standing how cannabinoids affect the function and development of the nervous system, and how these compounds can help managing neurodegenerative diseases.
JOSÉ CARLOS BOUSO
Psychologist and PhD in Pharmacology. His area of interest is Psychopharmacology and the therapeutic properties of entactogen and psychedelic drugs as well as of cannabis. He is currently the Scientific Projects Director of ICEERS Foundation, where he per-forms clinical studies on the therapeutic effects of ayahuasca, the medicinal properties of cannabis and the potential anti-addictive effects of ibogaine.
Associate Professor of Biochemistry and Molecular Biology at Complutense University (Madrid). Her main focus of re-search is the study of cannabinoid signal-ing in the oncologic context. Her goal is trying to understand in molecular terms and clinically exploit the antitumor potential of cannabinoids mainly in breast cancer.
Associate Professor of Biochemistry and Molecular Biology at Complutense University (Madrid). He has studied the potential anti-cancer use of the active compounds in marijuana for more than 15 years. His research has shed light on the molecular mechanisms under-lying cancer cell death induced by cannabinoids.
PhD in Biology and Assistant Professor at the University of Basque Country. His research focuses on understanding the role of the endocannabinoid system in the physiology of reproduction, both in animal models and humans. He collaborates with the patient association Dosemociones, coordinating the inflammatory bowel dis-eases group, treated with medicinal cannabis.
MARIANO GARCÍA DE PALAU
MD with 35-year experience in ER. He specializes in therapies with cannabinoids as palliative and coadjutants, in a non-invasive manner and complementing standard therapies. He collaborates with the magazine Soft Secrets, writing articles on the therapeutic uses of cannabis
MD, PhD, Associate Professor of Pediatrics at the School of Medicine, Autónoma University (Madrid). Head of the Neonatology Unit at San Carlos University Hospital. Her current line of research focuses on the neuroprotective role of cannabinoids, especially cannabidiol (CBD), in newborn hypoxic ischemia
Retired MD, specialized in the respiratory system. Since 2008, he collaborates with the Social Cannabis Club La Maca (Barcelona), guiding their members in the therapeutic use of cannabis. From 2010 to 2015 was a member of the Therapeutic team at the Catalan Federation of Cannabis Associations (CatFAC).
Family Doctor, he is a member of the Spanish Cannabinoid Research Society and of the International Association for Cannabinoids Medicines. He collaborates with Cáñamo and A Folha magazines, where he publishes articles on medicinal cannabis. He is the Director of the Therapeutic Offices of Madrid Federation of Cannabis Associations (MadFAC), Catalan Autoregulated Federation of Cannabis Associations (FEDCAC), Extremadura Federation of Cannabis Associations (FACEX).
During the second part of the Symposium, patients and patients associations will be the protagonists of the debate forums. They will ex-press their needs and requests as medicinal cannabis users, as well as the therapeutic benefits they obtain with these treatments.
Disclaimer: Views expressed here do not necessarily reflect those of Endoca and its staff. This article is not intended to provide medical advice, diagnosis, treatment or cure. Endoca CBD products have not been approved by the US Food and Drug Administration (FDA).